Teva Says U.S. Is Investigating Copaxone Marketing

NEW YORK (AP) -- Teva Pharmaceutical Industries says the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect.

The Israeli drugmaker says the U.S. Attorney's Office for the Southern District of New York wants it to provide documents related to the marketing of the drugs from Jan. 1, 2006, to the present. It says the government is conducting a civil investigation into possible violations of the False Claims Act, a law that allows the government to collect damages reported by private citizens.

Teva reported $4.33 billion in Copaxone sales in 2013.

Teva Pharmaceutical Industries Ltd. is the largest generic drug company in the world. In 2012 the company said the federal government was looking into allegations it paid bribes to government officials in Latin America.

More from

U.S. Companies Push Volunatry Labels On Modified Food

UAW Critics Take Differing Approaches To VW Vote

Apple Said To Take $14B Bite Of Stock Via Buyback

Explore more news here.

More in Operations